A detailed history of Farther Finance Advisors, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 107 shares of DNLI stock, worth $2,205. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107
Previous 80 33.75%
Holding current value
$2,205
Previous $1.76 Million 77.57%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$20.96 - $31.05 $565 - $838
27 Added 33.75%
107 $3.13 Million
Q2 2024

Jul 31, 2024

BUY
$14.96 - $23.22 $673 - $1,044
45 Added 128.57%
80 $1.76 Million
Q1 2024

May 13, 2024

SELL
$15.83 - $23.35 $775 - $1,144
-49 Reduced 58.33%
35 $720,000
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $1,360 - $1,947
84 New
84 $1.8 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.77B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.